NCT06441578 A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
| NCT ID | NCT06441578 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Thrombotic Thrombocytopenic Purpura (TTP) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-05-30 |
| Primary Completion | 2032-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-05-30 with a primary completion date of 2032-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a survey in Japan of recombinant ADAMTS13 used to treat or to prevent participants with congenital thrombotic thrombocytopenic purpura (cTTP). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from recombinant ADAMTS13 and to check if recombinant ADAMTS13 improves or prevents cTTP. During the study, participants with cTTP will take recombinant ADAMTS13 intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from recombinant ADAMTS13 for 18 months.
Eligibility Criteria
Inclusion Criteria: \- All participants with congenital thrombotic thrombocytopenic purpura (cTTP), treated with recombinant ADAMTS13 Exclusion Criteria: \- None
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT06441578 clinical trial?
This trial is open to participants of all sexes, studying Thrombotic Thrombocytopenic Purpura (TTP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06441578 currently recruiting?
Yes, NCT06441578 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT06441578 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT06441578 clinical trial?
NCT06441578 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 40 participants.